- Experimental measurement and correlation of the solubilities of 2,4-dichloro-5-methoxypyrimidine in ethyl ethanoate, methanol, ethanol, acetone, tetrachloromethane, and heptane at temperatures between (295 and 320) K
-
The solid-liquid equilibrium of 2,4-dichloro-5-methoxypyrimidine was first determined in this article. Using a laser monitoring observation technique, the solubilities of 2,4-dichloro-5-methoxypyrimidine in ethyl ethanoate, methanol, ethanol, acetone, tetrachloromethane, and heptane have been determined experimentally from (295.60 to 316.39, 302.37 to 316.95, 299.44 to 316.61, 297.35 to 311.37, 298.60 to 312.15, and 298.10 to 320.08) K, respectively. The results are correlated with λ-h equation and Apelblat equation. The calculated results show that the correlation of the Apelblat model for six measured systems has less deviation than that of the λ-h equation.
- Liu, Yong-Jie,Luo, Ting-Liang,Yao, Xin-Ding,Mao, Zhi-Bo,Liu, Guo-Ji
-
-
Read Online
- Preparation method of 2-chloro-5-methoxypyrimidine
-
The invention relates to the field of compound preparation methods, and in particular relates to a preparation method of 2-chloro-5-methoxypyrimidine, which is prepared by taking methyl methoxyacetateas a raw material. The product prepared by the preparation method has high purity, the catalyst and the solvent can be recycled, the reaction is mild, the control is easy, and the method is suitablefor industrial production.
- -
-
Paragraph 0018-0023
(2019/10/23)
-
- Solvent-free or low-solvent large-scale preparation of chloropyrimidine and analogues
-
Chloropyrimidine or other N-containing aromatic heterocyclic analogues can be efficiently prepared from the corresponding hydroxylated precursors under solvent-free or low-solvent conditions with equimolar or less chlorinating reagents. This high-yielding protocol allows successful preparations of multigram and kilogram batches of these important synthetic intermediates.
- Sun, Zhihua,Wang, Han,Wen, Kun,Li, Ya,Fan, Erkang
-
experimental part
p. 4149 - 4153
(2011/07/07)
-
- COMPOUNDS
-
A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof: wherein R1 is CN; R2 is H or F; R3 and R4 are independently hydrogen, fluorine, chlorine or OR5; R5 is hydrogen, C1-6 alkyl, C1-6 alkenyl or C1-6 alkynyl; R6 and R7 are independently hydrogen, halogen, OR8 or NR9R10; R8 is hydrogen or C1-6 alkyl; R9 and R10 are independently hydrogen or C1-6 alkyl; or the groups R9 and R10 when they are attached to a nitrogen atom may together form a 5- or 6-membered ring which optionally contains one further heteroatom selected from NR8, S and O said 5 or 6 membered ring being optionally substituted by hydroxyl or C1-6 alkoxy; or the groups R9 and R10 when they are attached to a nitrogen atom may together form an azetidinyl ring optionally substituted by hydroxyl or C1-6 alkoxy, is provided. The use of such compounds in treating amyloid-related disease is also disclosed.
- -
-
Page/Page column 24
(2011/12/04)
-
- NOVEL PYRIMIDINE COMPOUNDS AS MTOR AND P13K INHIBITORS
-
The present invention relates to pyrimidine compounds of formula (I): which are useful in treating mTOR kinase- or PI3K kinase-related diseases.
- -
-
Page/Page column 109-110
(2011/07/30)
-
- COMPOUNDS
-
A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof wherein X is N or CH; Q is NR6 or O; A1 and A2 are independently hydrogen or C1-6 alkyl or may together form a carbonyl group; R1 and R2 are independently hydrogen, halogen, CF3, CN, OR7, OR8, NR8R9, NR8COR10, NR8S02R10, S02NR8R9, SO2R10 or C1-6 alkyl optionally and independently substituted by one or more of hydroxyl, C1-6 alkoxy, halogen or NR8 R9; R 3 is hydrogen, halogen, CF3 or OR 7; R4 is hydrogen, halogen, CF3, OR8, NR8R9, NR8COR10, NR8S02R10 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR 8 R 9; or when R3 and R4 are positioned ortho and taken together form -0(CH2)mO-, where m is 1-3; R5 is hydrogen or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR8 R9; R6 is hydrogen or C1-6 alkyl; R7 is hydrogen or C1-6 alkyl optionally substituted by OR8 or NR8R9; R8 is hydrogen, C1-6 alkyl, optionally substituted by hydroxyl or C1-6 alkoxy or C1-3 alkylphenyl wherein said phenyl group is optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OR7, NR8R9 or OCF3; or the groups R8 and R9 when they are attached to a nitrogen atom may together form a 5- or 6-membered ring which optionally contains one further heteroatom selected from NR7, S and O said 5 or 6 membered ring being optionally substituted by hydroxyl or C1-6 alkoxy; or the groups R8 and R9 when they are attached to a nitrogen atom may together form an azetidinyl ring optionally substituted by hydroxyl or C1-6 alkoxy; and R10 is C1-6 alkyl or a phenyl group optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OCF3 or OR7; and n is 1 or 2. The use of the compounds in treating amyloid disease is also disclosed.
- -
-
Page/Page column 26; 27
(2011/12/04)
-
- Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV
-
The discovery of two classes of heterocyclic dipeptidyl peptidase IV (DPP-4) inhibitors, pyrimidinones and pyrimidinediones, is described. After a single oral dose, these potent, selective, and noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and lowering of blood glucose in animal models of diabetes. Compounds 13a, 27b, and 27j were selected for development.
- Zhang, Zhiyuan,Wallace, Michael B.,Feng, Jun,Stafford, Jeffrey A.,Skene, Robert J.,Shi, Lihong,Lee, Bumsup,Aertgeerts, Kathleen,Jennings, Andy,Xu, Rongda,Kassel, Daniel B.,Kaldor, Stephen W.,Navre, Marc,Webb, David R.,Gwaltney, Stephen L.
-
scheme or table
p. 510 - 524
(2011/03/20)
-
- Falcipain inhibitors: Optimization studies of the 2-pyrimidinecarbonitrile lead series
-
Falcipain-2 and falcipain-3 are papain-family cysteine proteases of the malaria parasite Plasmodium falciparum that are responsible for host hemoglobin hydrolysis to provide amino acids for parasite protein synthesis. Different heteroarylnitrile derivatives were studied as potential falcipain inhibitors and therefore potential antiparasitic lead compounds, with the 5-substituted-2- cyanopyrimidine chemical class emerging as the most potent and promising lead series. Through a sequential lead optimization process considering the different positions present in the initial scaffold, nanomolar and subnanomolar inhibitors at falcipains 2 and 3 were identified, with activity against cultured parasites in the micromolar range. Introduction of protonable amines within lead molecules led to marked improvements of up to 1000 times in activity against cultured parasites without noteworthy alterations in other SAR tendencies. Optimized compounds presented enzymatic activities in the picomolar to low nanomolar range and antiparasitic activities in the low nanomolar range.
- Coterón, Jose M.,Catterick, David,Castro, Julia,Chaparro, María J.,Díaz, Beatriz,Fernández, Esther,Ferrer, Santiago,Gamo, Francisco J.,Gordo, Mariola,Gut, Jiri,De Las Heras, Laura,Legac, Jennifer,Marco, Maria,Miguel, Juan,Mu?oz, Vicente,Porras, Esther,De La Rosa, Juan C.,Ruiz, Jose R.,Sandoval, Elena,Ventosa, Pilar,Rosenthal, Philip J.,Fiandor, Jose M.
-
experimental part
p. 6129 - 6152
(2010/10/21)
-
- ANTHRANILAMIDE INHIBITORS OF AURORA KINASE
-
The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof; where R1, R2, R3, R4, r and s are as previously defined. Compounds of the present invention are useful in the treatment of diseases associated with Aurora kinase activity such as cancer.
- -
-
Page/Page column 15
(2008/12/07)
-